MX356586B - Formulaciones parenterales de vacunas contra los norovirus. - Google Patents
Formulaciones parenterales de vacunas contra los norovirus.Info
- Publication number
- MX356586B MX356586B MX2014000411A MX2014000411A MX356586B MX 356586 B MX356586 B MX 356586B MX 2014000411 A MX2014000411 A MX 2014000411A MX 2014000411 A MX2014000411 A MX 2014000411A MX 356586 B MX356586 B MX 356586B
- Authority
- MX
- Mexico
- Prior art keywords
- vaccine formulations
- norovirus vaccine
- parenteral
- parenteral norovirus
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/16011—Caliciviridae
- C12N2770/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se refiere a composiciones de vacuna parenterales de dosis individuales que comprenden mezclas de partículas tipo virus monovalentes de Norovirus. También se divulgan métodos para conferir una inmunidad protectora contra infecciones por Norovirus en un ser humano por administración de dichas composiciones.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161506447P | 2011-07-11 | 2011-07-11 | |
PCT/US2012/046222 WO2013009849A1 (en) | 2011-07-11 | 2012-07-11 | Parenteral norovirus vaccine formulations |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2014000411A MX2014000411A (es) | 2014-08-26 |
MX356586B true MX356586B (es) | 2018-06-05 |
Family
ID=47506489
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014000411A MX356586B (es) | 2011-07-11 | 2012-07-11 | Formulaciones parenterales de vacunas contra los norovirus. |
Country Status (29)
Country | Link |
---|---|
US (5) | US9801934B2 (es) |
EP (3) | EP4112074A1 (es) |
JP (2) | JP6208659B2 (es) |
KR (1) | KR102096937B1 (es) |
CN (3) | CN105031637A (es) |
AU (2) | AU2012282658B2 (es) |
BR (1) | BR112014000656A2 (es) |
CA (1) | CA2841356C (es) |
CL (1) | CL2014000082A1 (es) |
CR (2) | CR20190540A (es) |
DK (1) | DK3299030T3 (es) |
DO (2) | DOP2014000004A (es) |
EA (3) | EA035442B1 (es) |
EC (1) | ECSP14013201A (es) |
ES (2) | ES2656527T3 (es) |
GE (1) | GEP201706668B (es) |
HK (3) | HK1198136A1 (es) |
IL (1) | IL230356B (es) |
MA (1) | MA35414B1 (es) |
MX (1) | MX356586B (es) |
MY (1) | MY170746A (es) |
PE (1) | PE20140845A1 (es) |
PH (1) | PH12018501515B1 (es) |
PL (2) | PL2731621T3 (es) |
SG (1) | SG10201605644WA (es) |
TN (1) | TN2014000008A1 (es) |
UA (1) | UA117732C2 (es) |
WO (1) | WO2013009849A1 (es) |
ZA (2) | ZA201401012B (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG174845A1 (en) | 2006-09-29 | 2011-10-28 | Ligocyte Pharmaceuticals Inc | Norovirus vaccine formulations |
US20100266636A1 (en) | 2007-09-18 | 2010-10-21 | Ligocyte Pharmaceuticals, Inc. | Method of conferring a protective immune response to norovirus |
JP2010539192A (ja) | 2007-09-18 | 2010-12-16 | リゴサイト ファーマスーティカルズ,インコーポレイテッド | ノロウイルスに対して防御免疫応答を付与する方法 |
ES2656527T3 (es) | 2011-07-11 | 2018-02-27 | Takeda Vaccines, Inc. | Formulaciones parenterales de vacunas de norovirus |
AU2014329403B2 (en) | 2013-10-03 | 2020-10-08 | Takeda Vaccines, Inc. | Methods of detection and removal of rhabdoviruses from cell lines |
EP3085357B1 (en) | 2013-12-16 | 2019-02-13 | Takeda Pharmaceutical Company Limited | Microneedle |
CN107184970A (zh) * | 2017-02-16 | 2017-09-22 | 北京生物制品研究所有限责任公司 | 口服诺如病毒亚单位疫苗及lt作为该疫苗佐剂的用途 |
GB201703644D0 (en) | 2017-03-07 | 2017-04-19 | Elopak As | Improvements in or relating to toller mounting arrangements |
WO2018210804A1 (en) * | 2017-05-15 | 2018-11-22 | Janssen Vaccines & Prevention B.V. | Stable virus-containing composition |
EP3752185A1 (en) * | 2018-02-15 | 2020-12-23 | Icon Genetics GmbH | Immunogenic composition and vaccine for generating an immune response to norovirus |
WO2019231712A1 (en) * | 2018-05-29 | 2019-12-05 | Stc.Unm | Virus-like particle compositions and methods of using same |
CN109265542B (zh) * | 2018-09-27 | 2021-06-15 | 国药中生生物技术研究院有限公司 | 特异性结合诺如病毒gii.4基因型vp1蛋白或vlp的抗体及其制备方法和应用 |
AR117462A1 (es) * | 2018-12-20 | 2021-08-04 | Takeda Vaccines Inc | Vacuna contra norovirus, formulaciones y métodos |
US20230285534A1 (en) * | 2020-01-08 | 2023-09-14 | Bharat Biotech International Limited | Viral vaccine compositions and methods of preparations thereof |
CA3213547A1 (en) | 2021-03-29 | 2022-10-06 | Naoshi Fukushima | Peptide of norovirus origin, polynucleotide, antibody, composition, method for identifying neutralizing epitope for norovirus |
JP2024519800A (ja) | 2021-05-21 | 2024-05-21 | タケダ ワクチン,インコーポレイテッド | 固体組成物、フリーズドライ方法およびガラスバイアル |
CN118252924A (zh) * | 2022-12-27 | 2024-06-28 | 远大赛威信生命科学(南京)有限公司 | 用于诱发哺乳动物针对诺如病毒的免疫反应的药物组合物及其制备方法和用途 |
Family Cites Families (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6572862B1 (en) | 1989-11-08 | 2003-06-03 | Baylor College Of Medicine | Methods and reagents to detect and characterize Norwalk and related viruses |
WO1992016543A1 (en) | 1991-03-25 | 1992-10-01 | Genelabs Incorporated | NORWALK VIRUS HUMAN GASTROENTERITIS AGENT AND MOLECULAR CLONING OF CORRESPONDING cDNAs |
AU683211B2 (en) | 1992-04-08 | 1997-11-06 | United States of America as represented by The Secretary Department of Health and Human Services, The | Wild-type measles virus glycoproteins: vaccine and detection method therefor |
WO1994005700A2 (en) | 1992-09-07 | 1994-03-17 | Baylor College Of Medicine | Methods and reagents to detect and characterize norwalk and related viruses |
DK0812593T4 (da) | 1993-03-23 | 2008-05-13 | Smithkline Beecham Biolog | Vaccinepræparater indeholdende 3-O-deacyleret monophosphoryllipid-A |
US5788970A (en) | 1994-03-29 | 1998-08-04 | The University Of Maryland College Park | Chimeric infectious bursal disease virus CDNA clones, expression products and vaccines based thereon |
ATE328068T1 (de) | 1994-05-16 | 2006-06-15 | Merck & Co Inc | Papillomavirus vakzine |
US5645051A (en) | 1995-04-21 | 1997-07-08 | Dura Pharmaceuticals, Inc. | Unit dose dry powder inhaler |
US5861241A (en) | 1995-08-16 | 1999-01-19 | University Of Massachusetts | Monoclonal antibodies for detecting Norwalk virus |
GB9525083D0 (en) | 1995-12-07 | 1996-02-07 | Danbiosyst Uk | Vaccine compositions |
US5834015A (en) * | 1996-09-11 | 1998-11-10 | Albany Medical College | Protein-lipid vesicles and autogenous vaccine comprising the same |
US5953727A (en) | 1996-10-10 | 1999-09-14 | Incyte Pharmaceuticals, Inc. | Project-based full-length biomolecular sequence database |
US6491919B2 (en) | 1997-04-01 | 2002-12-10 | Corixa Corporation | Aqueous immunologic adjuvant compostions of monophosphoryl lipid A |
PL336715A1 (en) | 1997-04-08 | 2000-07-03 | Merck & Co Inc | Stabilised formulation of human papilloma virus |
EP0980257A1 (en) | 1997-05-01 | 2000-02-23 | Chiron Corporation | Use of virus-like particles as adjuvants |
US20040265377A1 (en) | 1997-10-27 | 2004-12-30 | Harry Seager | Solid dispersing vaccine composition for oral delivery |
BR9913026A (pt) | 1998-08-14 | 2001-09-25 | Merck & Co Inc | Processo de purificação de partìculas semelhantes a vìrus (vlps) de papilomavìrus recombinante, e, processo de preparação de um produto de vlp de papilomavìrus humano purificado adequado para uso em uma vacina para humano |
ES2262359T3 (es) | 1998-12-17 | 2006-11-16 | MERCK & CO., INC. | Particulas tipo virus sinteticas con epitores heterologos. |
SI1150712T1 (sl) * | 1999-02-05 | 2009-02-28 | Merck & Co Inc | Pripravek cepiva proti humanem papiloma virusu |
CA2375337C (en) | 1999-06-22 | 2012-09-25 | Naokazu Takeda | Srsv detection kit |
JP2002020399A (ja) | 2000-07-10 | 2002-01-23 | Osaka Prefecture | ノルウォークウイルス(nv)を認識するモノクローナル抗体 |
GB0118249D0 (en) | 2001-07-26 | 2001-09-19 | Chiron Spa | Histidine vaccines |
WO2003068163A2 (en) | 2002-02-14 | 2003-08-21 | Novavax, Inc. | Optimization of gene sequences of chimeric virus-like particles for expression in insect cells |
GB0206359D0 (en) | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
GB0206360D0 (en) | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
JP4902103B2 (ja) | 2002-04-11 | 2012-03-21 | メディミューン・エルエルシー | 凍結乾燥フォームによる生物活性材料の保存 |
GB0302218D0 (en) | 2003-01-30 | 2003-03-05 | Chiron Sri | Vaccine formulation & Mucosal delivery |
EP1545625B1 (en) | 2002-06-07 | 2011-08-24 | Kentucky Bioprocessing, LLC | Flexible vaccine assembly and vaccine delivery platform |
JP4598519B2 (ja) | 2002-06-20 | 2010-12-15 | サイトス バイオテクノロジー アーゲー | アジュバントとして使用するためのパッケージ化されたウィルス様粒子:調製法及び使用法 |
WO2004075829A2 (en) | 2003-01-30 | 2004-09-10 | Chiron Corporation | Adjuvanted influenza vaccine |
WO2004073652A2 (en) | 2003-02-20 | 2004-09-02 | Becton Dickinson And Company | Powder formulations of recombinant staphylococcal enterotoxin b (rseb) made by atmospheric spray-freeze drying for improved vaccination |
US8592197B2 (en) | 2003-07-11 | 2013-11-26 | Novavax, Inc. | Functional influenza virus-like particles (VLPs) |
US7879338B2 (en) | 2003-07-21 | 2011-02-01 | Boyce Thompson Institute For Plant Research | Vectors and methods for immunization against norovirus using transgenic plants |
JP2007537137A (ja) | 2003-09-24 | 2007-12-20 | モンタナ ステート ユニバーシティ | ノロウィルスモノクローナル抗体及びペプチド |
WO2005037223A2 (en) | 2003-10-15 | 2005-04-28 | Brigham And Women's Hospital, Inc. | Methods and compositions for immunomodulation |
US20050215501A1 (en) | 2003-10-24 | 2005-09-29 | Coley Pharmaceutical Group, Inc. | Methods and products for enhancing epitope spreading |
FR2863890B1 (fr) | 2003-12-19 | 2006-03-24 | Aventis Pasteur | Composition immunostimulante |
US7481997B1 (en) | 2004-02-12 | 2009-01-27 | Montana State University | Snow mountain virus genome sequence, virus-like particles and methods of use |
US20050260225A1 (en) | 2004-05-18 | 2005-11-24 | Goldberg Joanna B | Intranasal recombinant Salmonella vaccine encoding heterologous polysaccharide antigens |
CU23496A1 (es) | 2004-09-03 | 2010-02-23 | Ct Ingenieria Genetica Biotech | Composición vacunal contra el virus de la hepatitis c |
EA015907B1 (ru) | 2004-10-20 | 2011-12-30 | Санофи Пастер Байолоджикс Ко. | Рекомбинантный флавивирус и его применение |
GB0428394D0 (en) | 2004-12-24 | 2005-02-02 | Chiron Srl | Saccharide conjugate vaccines |
AU2006203985A1 (en) | 2005-01-05 | 2006-07-13 | Philadelphia Health And Education Corporation | Delivery vehicles, bioactive substances and viral vaccines |
US8168771B2 (en) | 2005-01-31 | 2012-05-01 | The Johns Hopkins University | Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants |
CN101203529A (zh) | 2005-02-18 | 2008-06-18 | 诺华疫苗和诊断公司 | 来自脑膜炎/脓毒症相关性大肠杆菌的蛋白质和核酸 |
BRPI0608455A2 (pt) | 2005-03-18 | 2010-01-05 | Cytos Biotechnology Ag | composição compreendendo conjugados de alérgenos de gato bem como vacinas, composições farmacêuticas e medicamentos contendo a mesma, e processo para sua produção |
US20070041999A1 (en) | 2005-06-01 | 2007-02-22 | Lada Rasochova | Production of multivalent virus like particles |
EP1736538A1 (en) | 2005-06-21 | 2006-12-27 | Cytos Biotechnology AG | Process for the preparative purification of virus-like-particles (VLPs) |
ES2514316T3 (es) | 2005-11-22 | 2014-10-28 | Novartis Vaccines And Diagnostics, Inc. | Partículas similares a virus (VLPs) de Norovirus y Sapovirus |
JP2007145775A (ja) | 2005-11-29 | 2007-06-14 | Falco Life Science:Kk | ノロウイルスgiの高感度検出方法 |
US20080029915A1 (en) * | 2006-08-02 | 2008-02-07 | Courtoy Nv | Rotary tablet press |
SG174845A1 (en) * | 2006-09-29 | 2011-10-28 | Ligocyte Pharmaceuticals Inc | Norovirus vaccine formulations |
EP2121011B1 (en) | 2006-12-06 | 2014-05-21 | Novartis AG | Vaccines including antigen from four strains of influenza virus |
KR20150098681A (ko) * | 2007-03-14 | 2015-08-28 | 다케다 백신즈 인코포레이티드 | 바이러스 유사 입자 정제 |
WO2009033229A1 (en) | 2007-09-12 | 2009-03-19 | Australian Centre For Plant Functional Genomics Pty Ltd | Plant seed active transcriptional control sequences |
JP2010539192A (ja) | 2007-09-18 | 2010-12-16 | リゴサイト ファーマスーティカルズ,インコーポレイテッド | ノロウイルスに対して防御免疫応答を付与する方法 |
US20100266636A1 (en) | 2007-09-18 | 2010-10-21 | Ligocyte Pharmaceuticals, Inc. | Method of conferring a protective immune response to norovirus |
KR101793161B1 (ko) | 2008-08-08 | 2017-11-03 | 다케다 백신즈 인코포레이티드 | 강화된 교차 반응성을 가진 복합체 캡시드 아미노산 서열들을 포함하는 바이러스-유사 입자들 |
WO2010084298A1 (en) * | 2009-01-22 | 2010-07-29 | Pharmathene Uk Limited | Stable vaccine compositions and methods of use |
KR20110132373A (ko) * | 2009-02-10 | 2011-12-07 | 노파르티스 아게 | 유행병-연관 주에 대한 인플루엔자 백신 요법 |
US20110070260A1 (en) | 2009-09-09 | 2011-03-24 | Baric Ralph S | Multivalent Immunogenic Compositions Against Noroviruses and Methods of Use |
JP2013517773A (ja) * | 2010-01-21 | 2013-05-20 | リゴサイト ファーマスーティカルズ,インコーポレイテッド | カリシウイルスウイルス様粒子上の標的化異種抗原提示 |
CA2798493A1 (en) * | 2010-05-26 | 2011-12-01 | Selecta Biosciences, Inc. | Synthetic nanocarrier combination vaccines |
ES2656527T3 (es) | 2011-07-11 | 2018-02-27 | Takeda Vaccines, Inc. | Formulaciones parenterales de vacunas de norovirus |
JOP20130186B1 (ar) | 2012-06-22 | 2021-08-17 | Takeda Vaccines Montana Inc | تنقية الجزيئات الشبيهة بالفيروسات |
US10975149B2 (en) | 2015-12-16 | 2021-04-13 | The Walter And Eliza Hall Institute Of Medical Research | Inhibition of cytokine-induced SH2 protein in NK cells |
EP3529359B1 (en) | 2016-10-18 | 2023-12-13 | Regents of the University of Minnesota | Tumor infiltrating lymphocytes for use in therapy |
BR112020022010A2 (pt) | 2018-05-03 | 2021-01-26 | Board Of Regents, The University Of Texas System | células exterminadoras naturais modificadas para expressar receptores de antígeno quimérico com bloqueio de checkpoint imunológico |
WO2020041192A1 (en) | 2018-08-20 | 2020-02-27 | Takeda Vaccines, Inc. | Vlp formulations |
AR117462A1 (es) | 2018-12-20 | 2021-08-04 | Takeda Vaccines Inc | Vacuna contra norovirus, formulaciones y métodos |
BR112021016046A2 (pt) | 2019-02-15 | 2021-11-09 | Editas Medicine Inc | Células assassinas naturais modificadas (nk) para imunoterapia |
-
2012
- 2012-07-11 ES ES12811916.1T patent/ES2656527T3/es active Active
- 2012-07-11 WO PCT/US2012/046222 patent/WO2013009849A1/en active Application Filing
- 2012-07-11 EA EA201792407A patent/EA035442B1/ru not_active IP Right Cessation
- 2012-07-11 EP EP22176978.9A patent/EP4112074A1/en active Pending
- 2012-07-11 SG SG10201605644WA patent/SG10201605644WA/en unknown
- 2012-07-11 PE PE2014000054A patent/PE20140845A1/es active IP Right Grant
- 2012-07-11 BR BR112014000656A patent/BR112014000656A2/pt not_active Application Discontinuation
- 2012-07-11 CN CN201510262891.2A patent/CN105031637A/zh active Pending
- 2012-07-11 PL PL12811916T patent/PL2731621T3/pl unknown
- 2012-07-11 JP JP2014520273A patent/JP6208659B2/ja active Active
- 2012-07-11 CR CR20190540A patent/CR20190540A/es unknown
- 2012-07-11 MX MX2014000411A patent/MX356586B/es active IP Right Grant
- 2012-07-11 EP EP17199372.8A patent/EP3299030B1/en active Active
- 2012-07-11 EP EP12811916.1A patent/EP2731621B1/en active Active
- 2012-07-11 KR KR1020147003571A patent/KR102096937B1/ko active IP Right Grant
- 2012-07-11 CN CN201810373895.1A patent/CN108567975A/zh active Pending
- 2012-07-11 EA EA202090699A patent/EA202090699A3/ru unknown
- 2012-07-11 CA CA2841356A patent/CA2841356C/en active Active
- 2012-07-11 GE GEAP201213384A patent/GEP201706668B/en unknown
- 2012-07-11 MY MYPI2014000073A patent/MY170746A/en unknown
- 2012-07-11 ES ES17199372T patent/ES2926487T3/es active Active
- 2012-07-11 DK DK17199372.8T patent/DK3299030T3/da active
- 2012-07-11 PL PL17199372.8T patent/PL3299030T3/pl unknown
- 2012-07-11 CN CN201280043691.2A patent/CN103874507A/zh active Pending
- 2012-07-11 AU AU2012282658A patent/AU2012282658B2/en active Active
- 2012-07-11 EA EA201490258A patent/EA029470B1/ru not_active IP Right Cessation
- 2012-11-07 UA UAA201401321A patent/UA117732C2/uk unknown
-
2013
- 2013-03-15 US US13/840,403 patent/US9801934B2/en active Active
-
2014
- 2014-01-07 IL IL230356A patent/IL230356B/en active IP Right Grant
- 2014-01-07 TN TNP2014000008A patent/TN2014000008A1/en unknown
- 2014-01-10 DO DO2014000004A patent/DOP2014000004A/es unknown
- 2014-01-10 CL CL2014000082A patent/CL2014000082A1/es unknown
- 2014-02-06 MA MA36741A patent/MA35414B1/fr unknown
- 2014-02-10 ZA ZA2014/01012A patent/ZA201401012B/en unknown
- 2014-02-11 CR CR20140069A patent/CR20140069A/es unknown
- 2014-02-11 EC ECSP14013201 patent/ECSP14013201A/es unknown
- 2014-11-21 HK HK14111772.5A patent/HK1198136A1/xx unknown
- 2014-12-18 HK HK14112697.5A patent/HK1199202A1/xx unknown
- 2014-12-18 HK HK16102061.2A patent/HK1215154A1/zh unknown
-
2015
- 2015-02-09 ZA ZA2015/00915A patent/ZA201500915B/en unknown
- 2015-02-19 AU AU2015200836A patent/AU2015200836B2/en active Active
- 2015-07-10 US US14/796,614 patent/US9867876B2/en active Active
-
2017
- 2017-05-02 JP JP2017091755A patent/JP6613259B2/ja active Active
- 2017-12-08 US US15/836,030 patent/US10675341B2/en active Active
-
2018
- 2018-07-06 PH PH12018501515A patent/PH12018501515B1/en unknown
-
2020
- 2020-06-05 US US16/894,291 patent/US11701420B2/en active Active
-
2022
- 2022-02-04 DO DO2022000030A patent/DOP2022000030A/es unknown
-
2023
- 2023-05-24 US US18/322,679 patent/US20230338503A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12018501515A1 (en) | Parenteral novovirus vaccine formulations | |
MY197723A (en) | Vaccine compositions for the prevention of dengue virus infection | |
PH12014502875A1 (en) | Vaccine compositions for prevention against dengue virus infection | |
MX352324B (es) | Vacunas multivalentes de nanovehiculos sinteticos. | |
EP2827869A4 (en) | COMPOSITIONS AND METHODS FOR IMPROVING THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ITS ANALOGUES INCLUDING MESOINDIGO | |
MD20140136A2 (ro) | Inhibitori ai virusului hepatic C | |
MX2012009581A (es) | Vacunas para su uso en la profilaxis y tratamiento de la enfermedad del virus de influenza. | |
GB201400609D0 (en) | Vaccine adjuvant composition comprising inulin particles | |
MX2013013801A (es) | Oligodesoxinucleotidos inmunoestimuladores. | |
MX346596B (es) | Oligodesoxinucleotidos inmunoestimuladores. | |
BR112015008417A8 (pt) | composição imunogênica, vacina, e, uso de uma composição imunogênica | |
PH12017500304A1 (en) | Vaccine compositions against dengue virus diseases | |
EP2931310A4 (en) | COMPOSITIONS, METHODS OF ADMINISTRATION AND USES OF TRIVALENT FORMULATIONS AGAINST DENGUE VIRUS | |
EA032913B1 (ru) | Препараты производных пиримидиндиона | |
EA201690378A1 (ru) | Вакцинные композиции против наркотической зависимости | |
EP2780009A4 (en) | METHODS AND COMPOSITIONS FOR ENHANCED IL-MEDICATION ADMINISTRATION AND EXTENDED DELIVERY FORMULATIONS | |
IN2013CH04314A (es) | ||
PH12015500708A1 (en) | Agent for enhancing immunity containing glutathione | |
UA106101C2 (uk) | Спосіб виготовлення медичних противірусних препаратів, що містять наночастинки, та препарат проти вірусів герпесу hiv і грипу h1n1, виготовлений за даним способом | |
IN2013MU03123A (es) | ||
EP2777712A4 (en) | AUXILIARY SUBSTANCES FOR POLYSACCHARIDIVES AND FORMULATIONS OBTAINED THEREFROM | |
UA106111C2 (uk) | Спосіб отримання людського інтерферону з використанням наночастинок оксиду церію |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |